clinically meaningful differences

Related by string. * Clinically : patented clinically proven . clinically localized prostate . clinically obese / MEANINGFUL . Meaningful : demonstrated clinically meaningful . clinically meaningful improvement . clinically meaningful improvements / diff erence . DIFFERENCE . DIFFERENCES : Make Difference Day . DIFFERENCES INCLUDE BUT ARE . citing irreconcilable differences * *

Related by context. All words. (Click for frequent words.) 67 pharmacokinetic interactions 66 statistically significant differences 65 TEAEs 65 tumor histology 65 K ras mutations 65 estramustine 64 statistically significant correlations 64 dose limiting toxicities 64 galiximab 64 nicardipine 64 APTIVUS r 64 riociguat 64 severe hypersensitivity reactions 64 pegylated liposomal doxorubicin 63 overlapping toxicities 63 MAGE A3 ASCI 63 QTc prolongation 63 plasma pharmacokinetics 63 intravenous bisphosphonates 63 MGd 63 β blockers 63 genotypic resistance 63 KRAS status 63 achieved statistical significance 63 anti leukemic 63 interferon alfa 2b 63 ß blockers 63 locoregional recurrence 63 LT NS# 63 interferon gamma 1b 63 hematological parameters 62 Fulvestrant 62 fulvestrant 62 biochemical abnormalities 62 MGUS 62 antiepileptics 62 oral antidiabetes drugs 62 imatinib therapy 62 clevidipine 62 Torsades de Pointes 62 CIMZIA TM certolizumab pegol 62 lenalidomide dexamethasone 62 AZILECT 62 renal toxicity 62 mycophenolate mofetil 62 poor metabolizers 62 tarenflurbil 62 pharmacodynamic properties 62 surrogate endpoint 62 laboratory abnormalities 62 TNF blocker therapy 62 QT prolongation 62 lipid lowering medications 62 fluvastatin 62 Subgroup analyzes 62 sirolimus stent 62 Doxil ® 62 mutated K ras 62 progression TTP 62 nadolol 62 abacavir lamivudine 62 cisplatin gemcitabine 62 dose proportionality 61 pharmacokinetic interaction 61 pharmacokinetic equivalence 61 PREZISTA r 61 haematologic 61 posaconazole 61 antiangiogenic agent 61 sorafenib Nexavar 61 cediranib 61 adrenal suppression 61 seliciclib 61 avosentan 61 Navelbine 61 erlotinib Tarceva 61 recurrent glioblastoma multiforme 61 HES CEL 61 discontinuations due 61 thromboembolic events 61 macrolide antibiotic 61 liposomal amphotericin B 61 #D#C# 61 noninferiority 61 endoscopic remission 61 HER2 expression 61 fosbretabulin 61 mTOR inhibitors 61 Xelox 61 Tasigna prolongs 61 elotuzumab 61 tigecycline 61 prospectively defined 61 flutamide 61 nephrotoxicity 61 non selective NSAIDs 61 strontium ranelate 61 NNRTI resistance 61 Carvedilol 61 teriflunomide 61 fosamprenavir 61 Pemetrexed 61 GFT# 61 Pegasys ® 61 ABCB1 61 ganetespib 61 antiandrogen 61 active comparator 61 irbesartan 60 FOLPI 60 S/GSK# 60 hypericin 60 FOLFIRI 60 glatiramer acetate 60 demonstrated antitumor activity 60 Baseline characteristics 60 DLTs 60 histologic subtype 60 clinically relevant 60 TOP2A 60 lipid lowering drugs 60 paroxetine Paxil 60 BEXXAR Therapeutic Regimen 60 tipranavir 60 HMG CoA reductase inhibitors 60 cardiac repolarization 60 TDF FTC 60 MYCAMINE 60 #mg BID [003] 60 hypercalcemia 60 calcineurin inhibitors 60 pharmacodynamic parameters 60 QT QTc 60 pentoxifylline 60 CCyR 60 antiarrhythmic 60 myopathy rhabdomyolysis 60 EGFR antibodies 60 hematologic toxicity 60 pharmacodynamic endpoints 60 antiproliferative effects 60 HIV HCV coinfected 60 histological subtype 60 bovine thrombin 60 prolonged QT interval 60 tolerability profiles 60 erythropoietic 60 relapsed MM 60 caspofungin 60 histologies 60 erlotinib Tarceva ® 60 virologic breakthrough 60 idarubicin 60 myeloproliferative diseases 60 UGT#A# * 60 rHuEPO 60 piroxicam 60 Multimeric 60 mycophenolic acid 60 CIMZIA TM 60 dosage regimens 60 mGluR5 NAM 60 GSK# [001] 60 antitumor effect 60 infliximab Remicade 60 nonrandomized 60 bezafibrate 60 antiangiogenic agents 60 trastuzumab Herceptin ® 60 oral diclofenac 60 pharmacodynamic PD 60 gemifloxacin 60 endothelin receptor antagonists 60 corrected QT interval 60 tocilizumab 60 acitretin 60 zoledronate 60 nelfinavir 60 Dasatinib 60 lipid lowering agents 60 paclitaxel eluting stents 60 limiting toxicity 60 voriconazole 60 Seliciclib 60 pharmacokinetic characteristics 60 desvenlafaxine succinate 60 colesevelam 60 aspirin clopidogrel 60 placebo controlled trials 60 PNH patients 59 decitabine 59 beta lactam antibiotic 59 MGN# 59 evaluating tivozanib 59 protease inhibitor PI 59 cardioprotective effects 59 EDEMA3 trial 59 selective modulator 59 clinicopathological 59 efavirenz EFV 59 tipranavir ritonavir 59 efalizumab 59 pyridostigmine 59 Adverse events 59 pertuzumab 59 Tarceva TM 59 delafloxacin 59 noninferior 59 monoamine oxidase inhibitors 59 GAMMAGARD 59 comparator arm 59 adalimumab Humira 59 Serious Adverse Events 59 hepatotoxicity 59 AChE inhibitors 59 complete cytogenetic response 59 heparanase 59 endometrial hyperplasia 59 nonmetastatic 59 IOP lowering 59 citalopram Celexa 59 mecamylamine 59 ATACAND 59 CANCIDAS 59 inflammatory biomarkers 59 antihypertensive drugs 59 pCR 59 tanespimycin 59 serum calcium 59 macrovascular events 59 troponin T 59 cardiotoxic 59 torsade de pointes 59 antiandrogens 59 chlorthalidone 59 murine models 59 Diovan HCT 59 idraparinux 59 #ME# 59 prognostic marker 59 lipid lowering therapies 59 thienopyridines 59 cardiac toxicity 59 systemically administered 59 hematopoietic cancers 59 immunomodulatory therapy 59 antiphospholipid antibodies 59 mapatumumab 59 pamidronate 59 antiarrhythmic drug 59 imatinib resistance 59 nevirapine Viramune 59 zafirlukast 59 DFMO 59 certolizumab 59 angiotensin converting enzyme inhibitors 59 Pegylated 59 Erlotinib 59 trabectedin 59 HER2 overexpression 59 RRMS patients 59 bendamustine 59 ischemic cardiovascular 59 aldosterone antagonists 59 KRAS mutation 59 micafungin 59 Primary endpoints 59 montelukast 59 tibolone 59 prognostic indicators 59 amifostine 59 oral antidiabetic 59 statin cholesterol lowering 59 Stent thrombosis 59 interferon alfa 59 pan HDAC inhibitor 59 Teriflunomide 59 hypersensitivity allergic reactions 59 cMET 59 uridine triacetate 59 dacarbazine 59 ritonavir boosted 59 administered subcutaneously 59 Panzem R NCD 59 viral kinetics 59 ZACTIMA 59 active moiety 59 SSRI antidepressant 59 alteplase 59 GnRH agonist 59 gp# vaccine 59 heavily pretreated 59 maximally tolerated dose 59 placebo controlled clinical trials 59 Xanafide 59 primidone 59 pulmonary toxicity 59 salmeterol fluticasone 59 galantamine 59 huC# DM4 59 leflunomide 59 FluCAM arm 59 DAVANAT 59 medically inoperable 59 fondaparinux 59 TNF antagonist 59 aripiprazole Abilify 59 anthracycline taxane 59 APOPTONE 59 adriamycin 59 receptor inhibitor 59 aldosterone antagonist 59 PEGylated anti 59 nondiabetic patients 59 Pharmacokinetics PK 59 oxaliplatin Eloxatin 59 localized prostate 59 tenofovir DF 59 secondary efficacy endpoints 59 standard chemotherapy regimen 59 rFVIIa 59 antitumour activity 59 ACEI ARB 59 Triapine R 59 cranial irradiation 59 CTAP# Capsules 59 fibrinolytic 59 Relapsing remitting MS 59 MDS MPD 59 mitochondrial toxicity 58 eosinophil count 58 nilotinib 58 tumor necrosis 58 insulin glargine 58 favorable pharmacokinetic profile 58 DCCR 58 antiplatelet medications 58 proteasome inhibitor 58 events SAEs 58 SAR# [004] 58 factor TNF 58 6R BH4 58 tricyclic antidepressant 58 torsades de pointes 58 Known hypersensitivity 58 VDAs 58 NATRECOR ® 58 advanced adenomas 58 ibandronate 58 ipsilateral stroke 58 HBeAg positive patients 58 Sudhir Agrawal D.Phil 58 antiangiogenic activity 58 Hematologic toxicity 58 dopamine receptor agonist 58 etanercept Enbrel 58 CYP#D# inhibitors 58 ACTOplus met XR 58 INVEGA ® 58 periprocedural MI 58 CYP#A# inhibitors 58 HMG CoA reductase inhibitor 58 patients evaluable 58 stratifying patients 58 anthracycline containing 58 alkylating agent 58 lumiracoxib 58 CIMZIA ™ 58 Pharmacokinetic 58 5alpha reductase 58 lanthanum carbonate 58 vandetanib 58 tenofovir emtricitabine 58 neoadjuvant 58 subgroup analyzes 58 clinically meaningful improvement 58 statistically significant p = 58 CYT# potent vascular disrupting 58 neutropenic fever 58 liposomal doxorubicin 58 IGFBP 3 58 corticosteroid therapy 58 prasugrel Effient 58 Avandia Actos 58 TNF antagonists 58 highly immunogenic 58 sunitinib 58 glargine 58 chlorambucil 58 CINQUIL 58 pomalidomide 58 tiotropium bromide 58 SSc 58 ZOMIG 58 macrovascular disease 58 viral kinetic 58 AST ALT 58 neutropenia dehydration dyspnea 58 Cardiotoxicity 58 oral antidiabetic medication 58 sitagliptin Januvia 58 titrated glipizide 58 DAPT 58 saline placebo 58 NATRECOR R 58 oxcarbazepine 58 immunomodulation 58 GP IIb IIIa inhibitors 58 tolvaptan 58 intravenous cyclophosphamide 58 selenium supplementation 58 Hepatotoxicity 58 Navelbine ® 58 weekly subcutaneous injections 58 FASLODEX 58 prespecified 58 tranylcypromine 58 CDK inhibitor 58 oral rivaroxaban 58 HGS ETR2 58 statistically significant correlation 58 nucleoside reverse transcriptase inhibitor 58 elevated ALT 58 insulin glulisine 58 lung cancer NSCLC 58 panitumumab Vectibix 58 pharmacodynamic markers 58 cardiovascular calcification 58 ARCOXIA 58 anakinra 58 gadobutrol 58 ZOLINZA 58 CR nPR 58 Secondary endpoints 58 immunopathology 58 Relapsed Refractory Multiple Myeloma 58 intact parathyroid hormone 58 Hurthle cell 58 DAS# remission 58 COREG 58 multivariate Cox 58 TORISEL 58 paricalcitol 58 clomipramine 58 ELACYT 58 mg RDEA# 58 LEP ETU 58 Faslodex 58 HGS ETR1 58 XELOX 58 nitrofurantoin 58 bleomycin 58 transaminase elevations 58 BYETTA exenatide injection 58 Oral corticosteroids 58 histologic 58 splenectomized patients 58 neutropaenia 58 chemopreventive agent 58 B7 H3 58 vinca alkaloid 58 vismodegib 58 prostate cancer CaP 58 APTIVUS ritonavir 58 receiving VELCADE 58 LC#m# vaccine 58 thrombogenic 58 cetuximab Erbitux 58 prospectively stratified 58 apolipoprotein B 58 dacarbazine chemotherapy 58 neratinib 58 carvedilol 58 quinolone antibiotics 58 Immunohistochemical analysis 58 chloride secretion 58 etanercept 58 sipuleucel T 58 IFN beta 58 microtubule targeting 58 Gleevec resistant 58 receptor blocker 58 hematologic adverse 58 pharmacologically active isomer 58 mg kg dose 58 azacitidine 58 tumor subtypes 58 virologic responses 58 Paxil paroxetine 58 sustained virological response 58 metastatic neuroendocrine tumors 58 potassium sparing diuretics 58 coxibs 58 cardiac troponin 58 tumorigenicity 58 Darinaparsin 58 benazepril 58 VaD 58 genotoxic 58 antiangiogenic therapy 58 NMDA antagonists 58 LY# [003] 58 CYP#C# genotype 58 bronchodilatory 58 nab paclitaxel 58 #mg doses [002] 58 taxane resistant 58 fluoropyrimidine 58 relapsed MCL 58 TNF inhibitor 58 Roche Pegasys 57 RLAI 57 neuroregenerative 57 HBeAg negative patients 57 tamoxifen Nolvadex ® 57 nodal metastasis 57 cytopenias 57 basal bolus regimen 57 PKCi 57 intravenous immunoglobulin IVIg 57 Aflibercept 57 relapsed SCLC 57 humanised monoclonal antibody 57 preclinically 57 simvastatin ezetimibe 57 interferon IFN 57 pharmacodynamics PD 57 complete remissions 57 thyrotropin levels 57 Taxol ® 57 opioid tolerant 57 nonclinical studies 57 entecavir 57 BCR ABL mutations 57 E. faecalis 57 headache nasopharyngitis 57 sulindac 57 neuropsychiatric symptoms 57 clinically meaningful 57 cisplatin vinorelbine 57 APOE e4 57 antiplatelet drugs 57 ExTRACT TIMI 57 androgen suppression 57 cytogenic 57 Gemzar ® 57 MetMAb 57 elevated LDH 57 imatinib 57 INCB# [003] 57 DACH platinum 57 univariate 57 fusion enhancers 57 immunohistochemical 57 intracranial hemorrhage ICH 57 androgen deprivation 57 androgen ablation 57 PEGylated interferon beta 1a 57 factor Xa 57 fibrate drugs 57 sonographic diagnosis 57 malignant polyps 57 Kaplan Meier analysis 57 ARB telmisartan 57 MenACWY CRM 57 Febrile neutropenia 57 VEGF inhibitors 57 follicular lymphoma FL 57 thrombotic events 57 antiepileptic drug 57 SCIg 57 cTnI 57 briakinumab 57 YONDELIS 57 imatinib Gleevec ® 57 mepolizumab 57 teratogenic effects 57 leukotriene receptor antagonists 57 crizotinib PF # 57 alfuzosin 57 DU #b 57 NAbs 57 eplerenone 57 RezularTM 57 oral prednisolone 57 Gefitinib 57 abciximab 57 pharmacokinetic PK 57 IgG antibody 57 Allovectin 7 ® 57 ribavirin therapy 57 thyroglobulin 57 nonhematologic adverse reactions 57 JAK inhibitors 57 xenograft models 57 docetaxel chemotherapy 57 captopril 57 somatostatin analog 57 oblimersen 57 GnRH agonists 57 LV dysfunction 57 ADAGIO study 57 reactogenicity 57 VKORC1 57 FOLFOX4 57 Navelbine R 57 randomized multicenter trial 57 sleeve lobectomy 57 evaluable 57 anti androgen 57 docetaxel Taxotere ® 57 cilostazol 57 radiolabeled TM# 57 ZYVOX 57 bicalutamide 57 intranasally administered 57 gonococcal 57 masitinib 57 Exforge HCT 57 tapentadol ER 57 REMICADE ® 57 definite stent thrombosis 57 postoperative chemotherapy 57 colesevelam HCl 57 thiopurine 57 pretransplant 57 asthma exacerbation 57 breast cancer subtypes 57 venlafaxine XR 57 antibody titer 57 XL# inhibits 57 pharmacodynamic effects 57 seroprotection 57 reboxetine 57 amprenavir 57 brostallicin 57 antimetabolite 57 response CCyR 57 placebo controlled studies 57 hydroxychloroquine 57 IGF IR 57 CA4P 57 pharmacokinetics PK 57 recurrent GBM 57 antiarrhythmic drugs 57 DOXIL 57 prednisone prednisolone 57 carcinoids 57 isoproterenol 57 ximelagatran 57 aminotransferase levels 57 MERLIN TIMI 57 Prilosec omeprazole 57 BRAF mutations 57 adjuvant therapies 57 receptor tyrosine kinase inhibitor 57 undetectable HBV DNA 57 sarcomatoid 57 tryptase 57 BoNTA 57 gemcitabine cisplatin 57 statistically significant 57 immunosuppressive agents 57 VP# [004] 57 sotalol 57 TIMP 1 57 goserelin 57 morphometric vertebral fractures 57 dasatinib Sprycel ® 57 PEG SN# 57 Tumor Response 57 PDE4 inhibitors 57 prucalopride 57 enalapril 57 antidepressant efficacy 57 dyslipidaemia 57 oxysterols 57 cobiprostone 57 NOLVADEX 57 MAOIs 57 lipid parameters 57 etiologic 57 Thiovir 57 denileukin diftitox 57 tipranavir r 57 myocardial infarctions 57 Combination therapy 57 guanfacine 57 dalteparin 57 nonsteroidal 57 immuno suppressive 57 RAPTIVA 57 hormone receptor status 57 Telintra 57 efaproxiral 57 clinically detectable 57 lenalidomide Revlimid R 57 EDEMA3 57 salmeterol HFA MDI 57 RAS blockers 57 nonischemic 57 LRP5 57 taxane refractory 57 thiazide diuretics 57 sertraline Zoloft 57 virologic failure 57 Aptivus ® 57 hypereosinophilic syndrome 57 colorectal adenoma 57 HER2 positive cancers 57 abatacept 57 Vidaza ® 57 busulfan 57 cytogenetic response 57 opioid naïve 57 Crestor rosuvastatin 57 myelodysplastic myeloproliferative diseases 57 KAPIDEX 57 oxycodone CR 57 resected pancreatic cancer 57 BZA CE 57 mg/m2 dose 57 esomeprazole 57 A3 adenosine receptor 57 pharmacokinetic parameters 57 intensive statin therapy 57 antimuscarinic 57 Linjeta TM 57 nonnucleoside reverse transcriptase inhibitors 57 candesartan cilexetil 57 hereditary deficiency 57 FOSRENOL ® 57 DAS# CRP 57 #ng/ml 57 gemcitabine carboplatin 57 immunomodulatory agents 57 multivariate analyzes 57 VAPRISOL 57 neutropenic patients 57 ergot alkaloids 57 achieved ACR# 57 β blocker 57 concomitant medications 57 ertapenem 57 apremilast 57 oral Hycamtin 57 mcg dose 57 sodium nitroprusside 57 Arranon 57 Mylotarg 57 microdose 57 Cytoxan 57 anticholinergic agents 57 CYP #A# 57 SGAs 57 pegylated interferons 57 thromboembolism 57 Valortim ® 57 serum antibody 57 tiagabine 57 PegIFN RBV 57 ENMD # 57 mTOR inhibition 57 Fludara 57 silymarin 57 venlafaxine Effexor 57 MULTAQ 57 canakinumab 57 thromboembolic 57 motesanib 57 angioedema 56 arbaclofen 56 Natalizumab 56 alkylating agents 56 squamous histology 56 polytherapy 56 Epivir HBV 56 Sanofi Aventis Taxotere 56 anti TNF 56 completely resected 56 iodixanol 56 perioperative complications 56 HORIZONS AMI trial 56 pyrexia mucositis sepsis febrile 56 griseofulvin 56 mitoxantrone 56 CBLC# 56 lamotrigine 56 4mg/kg 56 novel VDA molecule 56 nonfatal MI 56 airway responsiveness 56 adalimumab 56 relapsed ALL 56 oral olanzapine 56 NMIBC 56 oral prodrug 56 tacrolimus ointment 56 unconjugated 56 hepatocellular carcinomas 56 Pioglitazone 56 RE LY trial 56 Antitumor Activity 56 Thalomid ® 56 danazol 56 Taxotere ® 56 pharmacodynamic 56 aprepitant 56 Zoraxel 56 PSA nadir 56 -#.# log# copies mL 56 sirolimus eluting stents 56 linear pharmacokinetics 56 gastrointestinal perforation 56 pioglitazone 56 pharmacologic treatments 56 beta carotene supplementation 56 papillary renal cell carcinoma 56 Pharmacokinetic studies 56 antineoplastic 56 Vitaxin 56 LPV r 56 Non inferiority 56 skeletal metastases 56 Fingolimod 56 QT interval prolongation 56 AVE# 56 containing abacavir 56 oral antidiabetes 56 p# activation 56 peginterferon alfa 56 advanced adenoma 56 abacavir 56 cardiotoxicity 56 ARIMIDEX 56 Ambrisentan 56 angiotensin II receptor blockers 56 coagulation abnormalities 56 R lenalidomide 56 secretin 56 antiemetics 56 topotecan 56 familial clustering 56 cardiac glycoside 56 recurrent venous thromboembolism 56 ACEIs 56 deletion 5q 56 proteasome inhibitors 56 rizatriptan 56 chemosensitivity 56 Subgroup analysis 56 rilpivirine 56 tricyclic anti depressants 56 cisplatin resistant 56 EXJADE 56 hsCRP levels 56 antitumour 56 efficacy endpoints 56 elevated creatinine 56 plus COPEGUS 56 ACCORD Lipid 56 atazanavir ritonavir 56 ON #.Na 56 F FDG PET 56 Hedgehog inhibitor 56 #q# deletion 56 pituitary adenomas 56 deep venous thromboses 56 ascending dose 56 dose regimens 56 antiepileptic medications 56 alvespimycin 56 radioimmunotherapy RIT 56 nanomolar 56 antiretroviral naive 56 events TEAEs 56 ziconotide 56 ramelteon 56 DMARDS 56 cytotoxicity 56 immunomodulating 56 NRTIs 56 inhaled anticholinergics 56 RCTs 56 FUSILEV enhances 56 unknown etiology 56 transgene expression 56 hypermethylated 56 haloperidol Haldol 56 Capecitabine 56 favorable pharmacokinetic 56 EGFR mutation positive 56 Hematologic 56 symptomatic VTE 56 Telmisartan 56 paroxetine sertraline 56 neuroleptic 56 PROactive study 56 fluoxetine Prozac 56 darinaparsin 56 clobazam 56 TroVax ® 56 randomized controlled trials RCTs 56 low dose cytarabine 56 composite endpoint 56 SCr 56 biologic DMARD 56 PEG IFN 56 vWF 56 IFN α 56 KIF6 carriers 56 Adalimumab 56 dexrazoxane 56 candidemia 56 phosphodiesterase type 5 56 APTIVUS 56 secondary efficacy endpoint 56 pimozide 56 enzastaurin 56 rt PA 56 Lantus insulin 56 nephrotoxic 56 Bezielle 56 boosted protease inhibitor 56 coadministration 56 Apoptone 56 hepatotoxic 56 GEMZAR 56 transdermal estrogen 56 seropositivity 56 xanthine oxidase inhibitor 56 PXD# 56 OXi# 56 lapatinib Tykerb 56 induced sputum 56 NSAIDs ibuprofen 56 QTc interval 56 imatinib resistant 56 conjugated estrogen 56 cabazitaxel 56 TMP SMX 56 olanzapine LAI 56 FOLFOX 56 hypersensitivity reactions 56 basal cell nevus syndrome 56 BENICAR HCT 56 aromatase inhibitors AIs 56 Thrombotic events 56 urate lowering 56 virologic response 56 radezolid 56 multivariable Cox 56 ritonavir boosted protease inhibitor 56 alicaforsen enema 56 methotrexate monotherapy 56 neutralizing antibody 56 5FU 56 ORENCIA ® 56 Angioedema 56 seropositive patients 56 anticholinergics 56 treating neuropathic pain 56 sulphonylureas 56 RoACTEMRA 56 platelet inhibitor 56 FTIs 56 kinase inhibition 56 clodronate 56 BRAF inhibitor 56 grade serous ovarian 56 Mg Uk 56 indinavir 56 ALB # 56 temsirolimus 56 potentially hepatotoxic 56 APOE genotype 56 TELCYTA 56 Akt inhibitor 56 interferon beta therapy 56 GOUT 56 pegylated interferon alfa 2b 56 hepatic enzyme 56 pravastatin 56 cryptogenic 56 CYP#D# genotype 56 pathophysiologic 56 Lp PLA 2 56 prednisone prednisolone plus 56 pegylated interferon alfa 56 orally bioavailable 56 diagnostic biomarker 56 MEK inhibitors 56 RISPERDAL ® 56 everolimus eluting stents 56 heavily pretreated patients 56 intima media thickness 56 divalproex sodium 56 ABC/3TC 56 5-FU/LV

Back to home page